Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Public ClinicalTrials.gov record NCT07700979. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Multi-regional Phase 3 Study of Cadonilimab Combined With Chemotherapy Versus Chemotherapy in Combination With or Without Nivolumab for the First-line Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.
Study identification
- NCT ID
- NCT07700979
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 900 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 24, 2026 (Actual)
- Primary completion
- Aug 18, 2029 (Estimated)
- Completion
- Aug 18, 2030 (Estimated)
- Last update posted
- Sep 29, 2026
2026 – 2030
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 | Not yet recruiting |
| UCLA Health | Los Angeles | California | 90095 | Not yet recruiting |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | Not yet recruiting |
| Yale School of Medicine | New Haven | Connecticut | 06510 | Not yet recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Not yet recruiting |
| Henry Ford Health | Detroit | Michigan | 48202 | Not yet recruiting |
| Mount Sinai | New York | New York | 10029 | Not yet recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Not yet recruiting |
| Oregon Health and Science University | Portland | Oregon | 97239 | Not yet recruiting |
| Sarah Cannon Research Institute (SCRI) - Oncology Partners | Nashville | Tennessee | 37203 | Not yet recruiting |
| Baylor Scott & White Health | Dallas | Texas | 75246 | Not yet recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Not yet recruiting |
| University of Wisconsin Carbone Cancer Center | Madison | Wisconsin | 53792 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07700979, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 29, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07700979 live on ClinicalTrials.gov.